Results of clinical developments of early triple negative breast cancer drug treatment: ASCO - 2022

Introduction. This article continues the series of reviews of innovative clinical developments related to drug therapy for leading cancers following the ASCO-2022 Annual Congress. This time we are seeing the results of therapy for early triple negative breast cancer (hereinafter referred to as TNR) is a consequence of the fact that TNR accounts for 15–20% of cases of all breast cancers, while it is the subtype of breast cancer (hereinafter referred to as BC), for which the choice of treatment methods is significantly limited. In Russia, state tasks have been set within the framework of the Federal project “Fight against cancer”, which provide for a significant reduction in mortality from neoplasms, including by improving the quality and effectiveness of drug treatment. Materials and methods. This scientific review is based on the results of a search in the databases of the digital educational platform MEDtalks.nl, PubMed/Medline and Google. Dictionary forms were used in the search strings: "kanker", "vroeg stadium", "triple negatief", "mammacarcinoom", "clinical trials", "ASCO-2022" and others in Dutch and English. Results and conclusion. The results presented in this article once again substantiate the prospects for further determination of algorithms for biomarker-personalized immunotherapy (in particular, pembrolizumab) as part of the combined antitumor treatment of RMZHER–/PR–/HER2– at early stages. Radiogenomics/radioproteomics technologies are a prime example of low-cost diagnostic tools that allow promptly suggesting a personalized tumor portrait in the period before biopsy. Further improvement of clinical oncoinformatics technologies (rather large arrays of omics data have already been accumulated) will contribute to a better understanding of programs for individualized choice of differentiated therapy for cancer patients, including patients with RMZHER–/PR–/HER2–. For citation: Andreev DA, Zavyalov AA. Results of clinical developments of early triple negative breast cancer drug treatment: ASCO-2022. City Healthсare. 2022;3(4): 122–131 doi: 10.47619/2713-2617.zm.2022.v.3i4;122–131